Clinical trial
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered…
NCT00441610 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00441610 |
|---|---|
| Title | An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor |
| Official title | An Extension Trial to a Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Advanced Solid Tumors |
| Intervention type | Drug |
| Interventions | Gimatecan |
| Enrollment | 4 |
| Start date | Jan 1, 2007 |
| Primary completion | Sep 1, 2009 |
| First posted | Mar 1, 2007 |
| Last update posted | Dec 19, 2020 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: